{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T02:05:47Z","timestamp":1767665147880,"version":"3.41.0"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>High-specific-activity <jats:sup>131<\/jats:sup>I-MIBG (Azedra) is the only Food and Drug Administration\u2013approved therapy for metastatic pheochromocytomas and paragangliomas, which are rare neuroendocrine tumors with limited treatment options. Based on our experience, we proposed here functional imaging-based tumor response criteria for these patient cohorts. Each response category was illustrated with typical sample cases, and clinical correlation was provided.<\/jats:p>","DOI":"10.1097\/rlu.0000000000004598","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:01:07Z","timestamp":1675987267000},"page":"320-323","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Proposed MIBG Scan\u2013Based Tumor Response Criteria of High-Specific-Activity 131I-MIBG Therapy in Metastatic Pheochromocytoma\/Paraganglioma"],"prefix":"10.1097","volume":"48","author":[{"given":"Yang","family":"Lu","sequence":"first","affiliation":[{"name":"Division of Diagnostic Imaging, Department of Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guofan","family":"Xu","sequence":"additional","affiliation":[{"name":"Division of Diagnostic Imaging, Department of Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilo","family":"Jimenez","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,2,8]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators","volume":"96","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"101354","DOI":"10.1016\/j.beem.2019.101354","article-title":"Metastatic pheochromocytoma and paraganglioma: management of endocrine manifestations, surgery and ablative procedures, and systemic therapies","volume":"34","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.3390\/jcm9082435","article-title":"Cardiovascular manifestations and complications of pheochromocytomas and paragangliomas","volume":"9","year":"2020","journal-title":"J Clin Med"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1210\/jc.2018-01968","article-title":"Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono study): a European network for the study of adrenal tumors retrospective study","volume":"104","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity (131)I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","year":"2019","journal-title":"J Nucl Med"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.3390\/cancers11071018","article-title":"Targeted radionuclide therapy for patients with metastatic pheochromocytoma and paraganglioma: from low-specific-activity to high-specific-activity iodine-131 metaiodobenzylguanidine","volume":"11","year":"2019","journal-title":"Cancers (Basel)"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/MED.0000000000000544","article-title":"High-specific-activity iodine 131 metaiodobenzylguanidine for the treatment of metastatic pheochromocytoma or paraganglioma: a novel therapy for an orphan disease","volume":"27","year":"2020","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11912-022-01197-0","article-title":"New directions in treatment of metastatic or advanced pheochromocytomas and sympathetic paragangliomas: an American, contemporary, pragmatic approach","volume":"24","year":"2022","journal-title":"Curr Oncol Rep"},{"journal-title":"Clin Nucl Med","article-title":"Functional imaging evidence of tumor response to high-specific-activity 131I-MIBG therapy in an 84-year-old patient with metastatic pheochromcytoma\/paraganglioma","year":"2023","key":"bib9-20250621"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004598","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:05:16Z","timestamp":1750536316000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,8]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004598","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"type":"electronic","value":"1536-0229"},{"type":"print","value":"0363-9762"}],"subject":[],"published":{"date-parts":[[2023,2,8]]}}}